These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2523663)

  • 61. Isradipine in the treatment of hypertension: a clinical profile.
    Vidt DG
    Cleve Clin J Med; 1990; 57(8):677-84. PubMed ID: 2147874
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus.
    Klauser R; Speiser P; Gisinger C; Schernthaner G; Prager R
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S93-6. PubMed ID: 1695314
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-term effects of isradipine on blood pressure and renal function.
    Pedersen OL; Krusell LR; Sihm I; Jespersen LT; Thomsen K
    Am J Med; 1989 Apr; 86(4A):15-8. PubMed ID: 2523650
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antihypertensive effect of isradipine on blood pressure at rest and during exercise.
    Dvorák I; Blaha M; Nĕmcová H
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):144S-146S. PubMed ID: 1673616
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group.
    Jern S; Hansson L; Scherstén B; Kullman S; Sörensen S; Dahlöf B; Eggertsen R; Sivertsson R
    J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S7-8. PubMed ID: 1720487
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cardiovascular effects of isradipine (Lomir) with special emphasis on haemodynamics and antihypertensive efficacy. A review.
    Dahlöf B
    Cor Vasa; 1990; 32(2 Suppl 1):23-34. PubMed ID: 2143458
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension.
    Dingemanse J; Otasevic P; Shakeri-Nejad K; Klainman E; Putnikovic B; Kracker H; Mueller MS; Zimlichman R
    J Hum Hypertens; 2015 Apr; 29(4):229-35. PubMed ID: 25231512
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Quantification of pedal edema during treatment with S(-)-amlodipine nicotinate versus amlodipine besylate in female Korean patients with mild to moderate hypertension: a 12-week, multicenter, randomized, double-blind, active-controlled, phase IV clinical trial.
    Oh GC; Lee HY; Kang HJ; Zo JH; Choi DJ; Oh BH
    Clin Ther; 2012 Sep; 34(9):1940-7. PubMed ID: 22925988
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of the new calcium entry blocker isradipine (PN 200-110) in essential hypertension.
    Staessen J; Lijnen P; Fagard R; Hespel P; Tan WP; Devos P; Amery A
    J Cardiovasc Pharmacol; 1989 Feb; 13(2):271-6. PubMed ID: 2468957
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treatment of essential hypertension with PN 200-110 (isradipine).
    Hamilton BP
    Am J Cardiol; 1987 Jan; 59(3):141B-145B. PubMed ID: 2949585
    [TBL] [Abstract][Full Text] [Related]  

  • 71. FDA approves i.v. calcium-channel blocker.
    Thompson CA
    Am J Health Syst Pharm; 2008 Sep; 65(18):1686. PubMed ID: 18768991
    [No Abstract]   [Full Text] [Related]  

  • 72. Isradipine in monotherapy and in combination with bopindolol: results of a 3-month multicentre study in hypertensives.
    Dzúrik R; Fetkovská N; Dvorák I; Jonás P; Markuljak I; Petr P; Kotlík I; Widimský J
    Cor Vasa; 1990; 32(2 Suppl 1):42-53. PubMed ID: 1974488
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A comparison of the safety of therapeutically equivalent doses of isradipine and diltiazem for treatment of essential hypertension.
    Black HR; Lewin AJ; Stein GH; MacCarthy EP; Hamilton JH; Hamilton BP; Madias NE; Kochar MS; Abrams AP; Isaacsohn JL
    Am J Hypertens; 1992 Mar; 5(3):141-6. PubMed ID: 1533528
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Acute antihypertensive and renal effects of isradipine in hypertensive patients with normal and reduced renal function.
    Wittenberg C; Rosenfeld JB
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):191S-193S. PubMed ID: 1827019
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The antihypertensive action of isradipine in mild essential hypertension.
    Viskoper JR; Laszt A; Farragi D
    J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S9-11. PubMed ID: 1720488
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Isradipine in the treatment of mild to moderate essential hypertension.
    Leary WP; Maharaj B; Van der Byl K
    S Afr Med J; 1991 Oct; 80(7):322-3. PubMed ID: 1833834
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Tasosartan Investigator's Group.
    Lacourcière Y; Pool JL; Svetkey L; Gradman AH; Larochelle P; de Champlain J; Smith WB
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):454-61. PubMed ID: 9607384
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Acute and short-term effects of new calcium antagonist in hypertension.
    Burris JF; Notargiacomo AV; Papademetriou V; Freis ED
    Hypertension; 1982; 4(3 Pt 2):32-5. PubMed ID: 7068206
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Platelet-activating effect of low-density lipoprotein and its reversal by isradipine.
    Fetkovská N; Fedelesová V; Kozlovský M; Dzúrik R
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):175S-177S. PubMed ID: 1827014
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hemodynamic study of short- and long-term isradipine treatment in patients with chronic ischemic congestive heart failure.
    McGrath BP; Newman R; Older P
    Am J Med; 1989 Apr; 86(4A):75-80. PubMed ID: 2523660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.